“This is an action beyond the DEA’s authority,” said Hoban Law Group Managing Partner Bob Hoban. Headquartered in Denver, Hoban Law Group specializes in cannabis law and policy. “This Final Rule serves to threaten hundreds, if not thousands, of growing businesses, with massive economic and industry expansion opportunities, all of which conduct lawful business compliant with existing policy as it is understood and in reliance upon the Federal Government.”
The petition, filed on January 13, 2017 in California’s United States Court of Appeals for the Ninth Circuit, is on behalf of three Petitioners: the Hemp Industries Association (an industrial hemp trade organization representing an array of industrial hemp industry actors); RMH Holdings, LLC (which sources its CBD products from industrial hemp lawfully cultivated pursuant to the Agricultural Act of 2014, also known as the Farm Bill); and Centuria Natural Foods, Inc. (which lawfully imports certain exempted parts of the Cannabis plant, and CBD oils and derivatives therefrom, such as stalks and fibers).
The recent Final Rule substantially impacts businesses long operating in compliance with existing laws that now could be facing significant change in existing policy. These adverse impacts are caused by the Final Rule’s attempt to create a drug code encompassing all cannabinoids as Schedule I substances without reflecting the parts of the Cannabis plant which are Congressionally exempted from the definition of “marihuana” under the Controlled Substances Act and/or are exempted from treatment as a controlled substance.
“Unfortunately, the DEA’s Final Rule exceeds the authority granted it by Congress and is inconsistent with the language of the Controlled Substance Act and other laws applying to industrial hemp,” Hoban Law Group’s press release states. “The genus Cannabis sativa L. contains over 80 cannabinoids, such as those commonly known as tetrahydrocannabinol (THC) and cannabidiol (CBD).
“The DEA’s Final Rule takes the position that the mere presence of any cannabinoid extracted from the Cannabis plant automatically renders that substance a ‘marihuana extract,’ despite no cannabinoid except for (synthetic) THC being expressly scheduled under the Controlled Substances Act,” according to Hoban Law Group. “This reclassification contradicts the DEA’s acknowledgement in the past that certain cannabinoids exhibit different effects: THC is known for psychoactive properties, whereas CBD, CBG and other cannabinoids are not commonly associated with psychoactive properties.
In addition, according to Hoban Law Group, the DEA’s Final Rule fails to recognize that cannabinoids can be derived from sources other than the Cannabis plant, such as a certain South African daisy, some chocolates, human breast milk and black pepper, highlighting the point that where or from what plant the cannabinoids originated is very difficult to prove.
“Whether the DEA’s motives are negligent or intentional, a primary concern is that this ‘mere recordkeeping’ is a misuse of the drug code that could lead to abuse and misunderstanding of the law by other local, state and federal agencies and an unwarranted chilling effect upon the industrial hemp industry,” Hoban Law Group’s prepared statement reads.
Notably, the DEA has sought to unilaterally reclassify cannabinoids before, and lost. See Hemp Indus. Ass’n. v. DEA, 357 F.3d 1012, 1014 (9th Cir. 2004); Hemp Indus. Ass’nv.DEA, 333 F.3d 1082, 1089 (9th Cir. 2003).